1-(3,5-dimethoxyphenyl)cyclopentanecarboxaldehyde | 339094-30-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,5-dimethoxyphenyl)cyclopentanecarboxaldehyde
• 英文别名: (3,5-Dimethoxyphenyl)cyclopentane carboxaldehyde；1-(3,5-dimethoxyphenyl)cyclopentane-1-carbaldehyde
• CAS: 339094-30-3
• 化学式: C₁₄H₁₈O₃
• 分子量: 234.295
• InChiKey: ODDXNFVRDOKBDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3,5-dimethoxyphenyl)cyclopentanecarboxaldehyde 在 palladium on activated charcoal 氢气 、 hexamethyldisilazide 、 三溴化硼 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 78.75h， 生成 5-(1-heptylcyclopentyl)resorcinol
  参考文献：
  名称：

  C1‘-Cycloalkyl Side Chain Pharmacophore in Tetrahydrocannabinols

  摘要：

  In earlier work we have provided evidence for the presence of a subsite within the CB1 and CB2 cannabinoid receptor binding domains of classical cannabinoids. This putative subsite corresponds to substituents on the C1'-position of the C3-alkyl side chain, a key pharmacophoric feature in this class of compounds. We have now refined this work through the synthesis of additional C1'-cycloalkyl compounds using newly developed approaches. Our findings indicate that the C1'-cyclopropyl and C1'-cyclopentyl groups are optimal pharmacophores for both receptors while the C1'-cyclobutyl group interacts optimally with CB1 but not with CB2. The C1'-cyclohexyl analogs have reduced affinities for both CB1 and CB2. However, these affinities are significantly improved with the introduction of a C2'-C3' cis double bond that modifies the available conformational space within the side chain and allows for a better accommodation of a six-membered ring within the side chain subsite. Our SAR results are highlighted by molecular modeling of key analogs.

  DOI：

  10.1021/jm070121a
• 作为产物：
  描述：

  3,5-二甲氧基苯基乙腈 在 双(三甲基硅烷基)氨基钾 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 1.13h， 生成 1-(3,5-dimethoxyphenyl)cyclopentanecarboxaldehyde
  参考文献：
  名称：

  大麻素侧链的药理学要求。在C1'处探测大麻素受体亚位点。

  摘要：

  我们实验室的早期工作为CB1和CB2大麻素受体结合域内存在一个亚位点提供了证据，该位点对应于经典大麻素苄基侧链位置的取代基。现在已经通过合成一系列带有C1'-环取代基的（-）-Delta（8）-四氢大麻酚类似物来探索该亚位点的存在和立体化学特征。在本文所述的化合物中，具有C1'-二硫杂环戊烷（1c），C1'-二氧戊环（2d）和环戊基（2a）取代基的化合物表现出对CB1和CB2的最高亲和力。我们使用分子建模方法更好地定义了假定亚位点的立体化学极限。体外药理测试发现1c是有效的CB1激动剂。

  DOI：

  10.1021/jm020558c

文献信息

• Pharmacophoric Requirements for the Cannabinoid Side Chain. Probing the Cannabinoid Receptor Subsite at C1‘
  作者：Demetris P. Papahatjis、Spyros P. Nikas、Therapia Kourouli、Ravi Chari、Wei Xu、Roger G. Pertwee、Alexandros Makriyannis

  DOI：10.1021/jm020558c

  日期：2003.7.1

  laboratories has provided evidence for the existence of a subsite within the CB1 and CB2 cannabinoid receptor binding domain corresponding to substituents at the benzylic side chain position of classical cannabinoids. The existence and stereochemical features of this subsite have now been probed through the synthesis of a novel series of (-)-Delta(8)-tetrahydrocannabinol analogues bearing C1'-ring substituents

  我们实验室的早期工作为CB1和CB2大麻素受体结合域内存在一个亚位点提供了证据，该位点对应于经典大麻素苄基侧链位置的取代基。现在已经通过合成一系列带有C1'-环取代基的（-）-Delta（8）-四氢大麻酚类似物来探索该亚位点的存在和立体化学特征。在本文所述的化合物中，具有C1'-二硫杂环戊烷（1c），C1'-二氧戊环（2d）和环戊基（2a）取代基的化合物表现出对CB1和CB2的最高亲和力。我们使用分子建模方法更好地定义了假定亚位点的立体化学极限。体外药理测试发现1c是有效的CB1激动剂。
• A New Ring-Forming Methodology for the Synthesis of Conformationally Constrained Bioactive Molecules
  作者：Demetris P. Papahatjis、Spyros Nikas、Andrew Tsotinis、Margarita Vlachou、Alexandros Makriyannis

  DOI：10.1246/cl.2001.192

  日期：2001.3

  A new, general, one pot method for introducing carbocyclic rings alpha to a nitrile moiety is described. Treatment of readily available arylacetonitriles with potassium bis(trimethylsilyl)amide and subsequent alkylation with α, ω-dibromo or dichloroalkanes in tetrahydrofuran under anhydrous conditions at 0 °C produces cycloalkyl adducts in good yields and short reaction times.

  描述了一种新的通用一锅法，用于在腈基前引入碳环。将 readily available 的芳基乙腈与氨基钾双(trimethylsilyl)处理，随后在无水条件下于0 °C的四氢呋喃中与α,ω-二溴或二氯烷烃进行烷基化，可以在短反应时间内以良好的产率生成环烷基附加物。
• Novel bicyclic and tricyclic cannabinoids
  申请人：——

  公开号：US20040236116A1

  公开（公告）日：2004-11-25

  Novel bicyclic-cannabinoids and hexahydrocannabinol analogs are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response useful to treat a number of physiological conditions.

  本发明提供了新型双环大麻素和六氢大麻酚类似物。当以治疗有效量给个体或动物施用这些化合物时，会导致个体或动物体内该化合物的水平足够高，从而引起生理反应。这种生理反应对于治疗多种生理状况非常有用。
• Novel Bicyclic Cannabinoids
  申请人：Makriyannis Alexandros

  公开号：US20070135388A1

  公开（公告）日：2007-06-14

  Bicyclic-cannabinoids and methods of preparation and use are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions.

  本文介绍了双环大麻素及其制备和使用方法。当以治疗有效量的这些化合物给个体或动物注射时，会在个体或动物体内产生足够高的该化合物水平，从而引起生理反应。这种生理反应可能对治疗多种生理状况有用。
• Bicyclic and tricyclic cannabinoids
  申请人：University of Connecticut

  公开号：US07285683B2

  公开（公告）日：2007-10-23

  Novel bicyclic-cannabinoids and hexahydrocannabinol analogs are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response useful to treat a number of physiological conditions.

  本文介绍了新型的双环式大麻素和六氢大麻酚类似物。当以治疗有效剂量给个体或动物施用这些化合物时，会在个体或动物中产生足够高的该化合物水平，从而引起生理反应。这种生理反应对于治疗许多生理疾病是有用的。